UNH - Obesity drug coverage among U.S. employers to nearly double in 2024: survey
2023-10-10 14:03:56 ET
More on Lilly, Novo, etc.
- Eli Lilly: Do Not Chase This Stock Over The Cliff
- Eli Lilly: Big Cancer Bet With Point Biopharma Global Purchase
- Eli Lilly POINTs Toward Radiopharmaceutical Ambitions
- Novo Nordisk lawsuit over compounded weight loss drugs dismissed
- Eli Lilly rebounds amid bullish views from analysts
For further details see:
Obesity drug coverage among U.S. employers to nearly double in 2024: survey